CORCEPT THERAPEUTICS INC 8-K

What Happened
On February 19, 2026 Corcept Therapeutics Incorporated announced (via Form 8-K and an attached press release) that the U.S. Court of Appeals for the Federal Circuit found Teva Pharmaceuticals’ marketing of a generic version of Korlym does not infringe two Corcept patents. The patents at issue cover methods for safely co‑administering Korlym with drugs that inhibit the CYP3A4 enzyme—drugs commonly prescribed to patients with Cushing’s syndrome.

Key Details

• Filing: Form 8-K filed February 19, 2026 (Item 8.01 Other Events); press release attached as Exhibit 99.1.
• Court: Decision by the United States Court of Appeals for the Federal Circuit.
• Subject: Teva’s marketing of a generic Korlym product found not to infringe two method-of-use patents related to co‑administration with CYP3A4 inhibitors.
• Scope: Ruling addresses infringement of two specific Corcept patents; the 8‑K does not provide financial amounts, timetable for Teva’s product launch, or note other patent proceedings.

Why It Matters
This federal appellate ruling removes two patent-based obstacles to Teva’s ability to market a generic version of Korlym, which could affect Corcept’s competitive position for that product. For investors, the decision is material because it relates directly to potential generic competition for Korlym—an important source of revenue—though the filing does not quantify any financial impact or note whether Corcept will seek further review. Monitor Corcept disclosures for updates on appeals, other patent claims, or financial guidance.